Comparative statistics by cancer registry

Table2b: Number and proportion of cases by vital status and median follow-up (in months) by site

(Singapore, 1993-1997 cases followed-up until 2001)

Click on cancer site (ICD-10 code) for comparison

Site	ICD-10	Total included	Dead		Alive		Complete FU		Median FU (in months)
Site	ICD-10	Total included	No.	%	No.	%	No.	%	Median FU (in months)
C01-02	Tongue	120	81	67.5	39	32.5	120	100.0	18.6
C03-06	Oral cavity	135	93	68.9	42	31.1	135	100.0	17.9
C07-08	Salivary gland	87	30	34.5	57	65.5	87	100.0	62.9
C09	Tonsil	38	25	65.8	13	34.2	38	100.0	34.4
C11	Nasopharynx	1404	659	46.9	745	53.1	1404	100.0	56.9
C12-13	Hypopharynx	90	84	93.3	6	6.7	90	100.0	10.0
C15	Oesophagus	446	424	95.1	22	4.9	446	100.0	5.3
C16	Stomach	2100	1727	82.2	373	17.8	2100	100.0	8.5
C17	Small intestine	80	63	78.8	17	21.3	80	100.0	12.9
C18	Colon	2501	1540	61.6	961	38.4	2501	100.0	37.8
C19-20	Rectum	1753	1064	60.7	689	39.3	1753	100.0	41.1
C21	Anus	53	39	73.6	14	26.4	53	100.0	22.6
C22	Liver	1550	1490	96.1	60	3.9	1550	100.0	2.2
C23-24	Gall bladder	289	261	90.3	28	9.7	289	100.0	5.2
C25	Pancreas	512	495	96.7	17	3.3	512	100.0	2.6
C30-31	Nose/Sinuses	71	45	63.4	26	36.6	71	100.0	34.9
C32	Larynx	311	174	55.9	137	44.1	311	100.0	45.9
C33-34	Lung	4253	4031	94.8	222	5.2	4253	100.0	5.4
C37-38	Other thoracic organs	63	37	58.7	26	41.3	63	100.0	39.1
C40-41	Bone	61	39	63.9	22	36.1	61	100.0	29.5
C43	Melanoma skin	60	41	68.3	19	31.7	60	100.0	31.6
C44	Other skin	1037	311	30.0	726	70.0	1037	100.0	67.2
C45	Mesothelioma	34	31	91.2	3	8.8	34	100.0	6.2
C47+C49	Connective tissue	166	84	50.6	82	49.4	166	100.0	49.7
C48	Peritoneum	40	30	75.0	10	25.0	40	100.0	18.9
C50	Breast	3204	1018	31.8	2186	68.2	3204	100.0	64.1
C51	Vulva	35	16	45.7	19	54.3	35	100.0	56.1
C53	Cervix	984	416	42.3	568	57.7	984	100.0	58.4
C54	Corpus uteri	483	124	25.7	359	74.3	483	100.0	63.6
C56	Ovary	718	293	40.8	425	59.2	718	100.0	59.0
C60	Penis	41	19	46.3	22	53.7	41	100.0	55.0
C61	Prostate	752	459	61.0	293	39.0	752	100.0	48.9
C62	Testis	75	11	14.7	64	85.3	75	100.0	71.8
C64	Kidney	369	211	57.2	158	42.8	369	100.0	34.6
C65	Renal pelvis	44	31	70.5	13	29.5	44	100.0	11.0
C67	Urinary bladder	496	252	50.8	244	49.2	496	100.0	52.2
C70-72	Brain & nervous system	290	211	72.8	79	27.2	290	100.0	15.0
C73	Thyroid	554	83	15.0	471	85.0	554	100.0	72.5
C74	Adrenal gland	28	18	64.3	10	35.7	28	100.0	22.6
C81	Hodgkin lymphoma	73	23	31.5	50	68.5	73	100.0	69.4
C82-85+C96	Non-Hodgkin lymphoma	790	472	59.7	318	40.3	790	100.0	23.2
C90	Multiple myeloma	159	138	86.8	21	13.2	159	100.0	16.1
C91	Lymphoid leukaemia	205	119	58.0	86	42.0	205	100.0	36.4
C92-94	Myeloid leukaemia	390	327	83.8	63	16.2	390	100.0	7.7
C95	Leukaemia unspecified	72	66	91.7	6	8.3	72	100.0	2.3

Other tables available for this registry:

- Table1:	Data quality indices - Proportion (%) of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site (Singapore, 1993-1997 cases followed-up until 2001)
- Table2b:	Number and proportion of cases by vital status and median follow-up (in months) by site (Singapore, 1993-1997 cases followed-up until 2001)
- Table3:	Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival (ASRS) by site (Singapore, 1993-1997 cases followed-up until 2001)
- Table4:	Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group (Singapore, 1993-1997 cases followed-up until 2001)
- Table5b:	Proportion (%) of cases and 5-year absolute survival by extent of disease and site (Singapore, 1993-1997)
- Table6:	Comparison of 5-year absolute and relative survival of cases diagnosed between 1988-1992 and 1993-1997 (Singapore)
- Table7b:	Number of cases by cancer site and calendar period (Singapore Cancer Registry, 1968-1997)
- Table8:	Up-to-date 5-year relative survival estimates using cohort and period approaches by site and calendar period (Singapore, 1968-1997 cases followed-up until 1997)
- Table9:	Up-to-date 10- and 15-year relative survival estimates using cohort and period approaches by site and calendar period (Singapore, 1968-1997 cases followed-up until 1997)

Registry chapter:

Consult the chapter in Cancer survival in developping countries (Volume II)

Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan)

Comparative statistics by cancer registry

Table2b: Number and proportion of cases by vital status and median follow-up (in months) by site